XML 36 R27.htm IDEA: XBRL DOCUMENT
v3.23.3

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES | SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES
|  | Initial Valuations (on new derivative instruments entered into during the year ended June 30, 2023)
Volatility |  | 228.29 – 256.02%
Expected Remaining Term (in years) |  | 0.22 – 0.28
Risk Free Interest Rate |  | 3.13 – 4.42%
Expected dividend yield |  | None
|  | June 30, 2023 |  |  | June 30, 2022 |
Volatility |  |  | 334.56 | % |  |  | 228 | %
Expected remaining term |  |  | 0.01 - 0.73 |  |  |  | 0.01 |
Risk-free interest rate |  |  | 5.24 | % |  |  | 1.28 | %
Expected dividend yield |  |  | None |  |  |  | None |
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS | SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS
|  | Balance at June 30, 2023 |  |  | Quoted Prices in Active Markets for Identical Assets |  |  | Significant Other Observable Inputs |  |  | Significant Unobservable Inputs |
|  |  |  |  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |
Embedded conversion option liabilities |  | $ | 423,209 |  |  | $ | — |  |  | $ | — |  |  | $ | 423,209 |
Total |  | $ | 423,209 |  |  | $ | — |  |  | $ | — |  |  | $ | 423,209 |
PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2022:
|  | Balance at June 30, 2022 |  |  | Quoted Prices in Active Markets for Identical Assets |  |  | Significant Other Observable Inputs |  |  | Significant Unobservable Inputs |
|  |  |  |  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |
Embedded conversion option liabilities |  | $ | 151,262 |  |  | $ | — |  |  | $ | — |  |  | $ | 151,262 |
Total |  | $ | 151,262 |  |  | $ | — |  |  | $ | — |  |  | $ | 151,262 |
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE | The following is a roll forward for the years ended June 30, 2023 and 2022 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE
|  | Fair Value of |
|  | Liability for |
|  | Derivative |
|  | Instruments |
Balance at June 30, 2021 |  | $ | 54,220 |
Initial fair value of embedded conversion option derivative liability recorded as debt discount |  |  | - |
Gain on debt extinguishment |  |  | (2,069 | )
Change in fair value included in statements of operations |  |  | 99,111 |
Balance at June 30, 2022 |  |  | 151,262 |
Beginning balance |  |  | 151,262 |
Initial fair value of embedded conversion option derivative liability recorded as debt discount |  |  | 93,668 |
Gain on debt extinguishment |  |  | (352,051 | )
Change in fair value included in statements of operations |  |  | 530,330 |
Balance at June 30, 2023 |  | $ | 423,209 |
Ending balance |  | $ | 423,209 |

X
- References No definition available. + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration